

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** WX0000003826 F 12/05/1988 34 Y

	Referral Te	•							
	Collected	1: 10/20/2023 12:10		10/20/2023	12:10				
<u>Test Name</u>	Result	<u>Flag</u> <u>Ref-Ra</u>	nges	<u>Units</u>	<u>Site</u>				
Phosphatidylethanol (PEth)	, WB, Quantitative								
PEth 16:0/18:1 (POPEth)	46			ng/mL	ARRI				
PEth 16:0/18:1 (POPEth) Less than 10 ng/mLNot detected Less than 20 ng/mLAbstinence or light alcohol consumption 20 - 200 ng/mLModerate alcohol consumption Greater than 200 ng/mLHeavy alcohol consumption or chronic alcohol use (Reference: W. Ulwelling and K Smith 2018 J. Forensic Sci)									
PEth 16:0/18:2 (PLPEth)	48	Reported Date:	2023.10.20	-:1 ng/mL	ARRI				
Reference ranges are not well established.									
EER_Phosphatidylethanol	See Note	Reported Date:	2023.10.20	-:1	ARR				
		Reported Date:	2023 10 20	-:1					
PEth Interpretation	See Note		2020.10.20	1	ARR				
formed in the present phosphatidylcholine. biomarker. The predor 16:0/18:1 (POPEth) and account for 37-46% and respectively. PEth is membrane of red blood 4-10 days and a window the window of detects chronically or excess quantification is 10 be helpful in monitor results should be into patient's clinical and Patients with advance elevated PEth concent	(PEth) is a group of phos ce of ethanol, phospholip PEth is known to be a di minant PEth homologues ar and PEth 16:0/18:2 (PLPEth and 26-28% of the total PE s incorporated into the p d cells and has a general ow of detection of 2-4 we ion is longer in individu sively consume alcohol. T ng/mL. Serial monitoring ring alcohol abstinence o terpreted in the context and behavioral history. ed liver disease may have trations (Nguyen VL et al & Experimental Research).	ase D and rect alcohol re PEth b), which th homologues, bhospholipid half-life of reks. However, tals who the limit of r of PEth may over time. PEth of the falsely 2018,							

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F420000017	Ordered By:	KAJAL SITWALA, MD, PhD	
WX000003826	WX000000002353		
Printed D&T: 10/20/23 12:11			



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 EXAMPLE, REPORT W WX0000003826 F 12/05/1988 34 Y

Referral Testing								
	Collected: 10/20/2023 12:10	Received: 10/20/2023	12:10					
<u>Test Name</u>	Result Flag Ref-Range	<u>es Units</u>	<u>Site</u>					
	This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes. Performed By: ARUP Laboratories 500 Chipeta Way Salt Lake City, UT 84108 Laboratory Director: Jonathan R. Genzen, MD, PhD CLIA Number: 46D0523979							

Reported Date: 2023.10.20 12:11 PETHQ

Performing Site: ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED